

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:138712-2019:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2019/S 060-138712**

Contract award notice

Results of the procurement procedure

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (Operating Under the Name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
Telephone: +44 1928755224
E-mail: david.ford1@nhs.net
NUTS code: UK

Internet address(es):

Main address: <https://nhsengland.bravosolution.co.uk>

I.2) Information about joint procurement

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

NHS National Generic Pharmaceuticals – Imatinib and Valganciclovir
Reference number: CM/PHG/18/5573

II.1.2) Main CPV code

33600000

II.1.3) Type of contract

Supplies

II.1.4) Short description:

Invitation to offer for NHS National Generic Pharmaceuticals – Imatinib and Valganciclovir
Offer reference number: CM/PHG/18/5573

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 17 months

Potential periods of call-offs under the Framework Agreement:
All products and all regions: 11.5.2019 to 31.1.2020 (8,5 months)

II.1.6) **Information about lots**

This contract is divided into lots: yes

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 2 763 678.00 GBP

II.2) **Description**

II.2.1) **Title:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir CESW Region
Lot No: 01

II.2.2) **Additional CPV code(s)**

33000000
33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir CESW region

Offer reference number: CM/PHG/18/5573

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 17 months

Potential periods of call-offs under the Framework Agreement:

All products and all regions: 11.5.2019 to 31.1.2020 (8,5 months).

II.2.5) **Award criteria**

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: In descending order

Price - Weighting: In descending order

II.2.11) **Information about options**

Options: yes

Description of options:

This Framework Agreement has the option to extend up to a period of 8,5 months.

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir NWLN Region
Lot No: 02

II.2.2) **Additional CPV code(s)**

33000000
33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir NWLN Region

Offer reference number: CM/PHG/18/5573

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 17 months

Potential periods of call-offs under the Framework Agreement:

All products and all regions: 11.5.2019 to 31.1.2020 (8,5 months).

II.2.5) **Award criteria**

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: In descending order

Price - Weighting: In descending order

II.2.11) **Information about options**

Options: yes

Description of options:

This Framework Agreement has the option to extend up to a period of 8,5 months.

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir LSNE Region

Lot No: 03

II.2.2) **Additional CPV code(s)**

33000000

33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to document 3, Schedule 8 in the ITO Documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir LSNE region

Offer reference number: CM/PHG/18/5573

Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 17 months

Potential periods of call-offs under the Framework Agreement:

All products and all regions: 11.5.2019 to 31.1.2020 (8,5 months).

II.2.5) **Award criteria**

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: In descending order

Price - Weighting: In descending order

II.2.11) **Information about options**

Options: yes

Description of options:

This Framework Agreement has the option to extend up to a period of 8,5 months.

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

IV.1.6) **Information about electronic auction**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Notice number in the OJ S: [2018/S 222-507515](#)

IV.2.8) **Information about termination of dynamic purchasing system**

IV.2.9) **Information about termination of call for competition in the form of a prior information notice**

Section V: Award of contract

Contract No: CM/PHG/18/5573

Lot No: 01

Title:

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir CESW Region

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

18/02/2019

V.2.2) **Information about tenders**

Number of tenders received: 16

Number of tenders received from SMEs: 4

Number of tenders received by electronic means: 16

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see section VI.3 for list of awarded suppliers

Please see section VI.3 for list of awarded suppliers

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 1 143 445.50 GBP

V.2.5) **Information about subcontracting**

Section V: Award of contract

Contract No: CM/PHG/18/5573

Lot No: 02

Title:

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir NWLN Region

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

18/02/2019

V.2.2) **Information about tenders**

Number of tenders received: 16

Number of tenders received from SMEs: 4

Number of tenders received by electronic means: 16

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see section VI.3 for list of awarded suppliers

Please see section VI.3 for list of awarded suppliers

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 842 811.60 GBP

V.2.5) **Information about subcontracting**

Section V: Award of contract

Contract No: CM/PHG/18/5573

Lot No: 03

Title:

NHS National Generic Pharmaceuticals — Imatinib and Valganciclovir LSNE

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

18/02/2019

V.2.2) **Information about tenders**

Number of tenders received: 16

Number of tenders received from SMEs: 4

Number of tenders received by electronic means: 16

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see section VI.3 for list of awarded suppliers
Please see section VI.3 for list of awarded suppliers
United Kingdom
NUTS code: UK
The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 777 420.94 GBP

V.2.5) **Information about subcontracting**

Section VI: Complementary information

VI.3) **Additional information:**

Please see list of awarded suppliers (Including SME status) at the following website:
<https://www.gov.uk/contracts-finder>

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Royal Courts of Justice
London or any other district registry of the High Court
United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

The NHS Commissioning Board (Operating under the name of NHS England)
Runcorn
United Kingdom

VI.5) **Date of dispatch of this notice:**

21/03/2019